Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity ...

Anifrolumab (Saphnelo) lowered the risk of long-term organ damage progression by about 60% The drug received federal approval in 2021 WEDNESDAY, Feb. 19, 2025 (HealthDay News) -- Lupus can do ...

Saphnelo (anifrolumab) is the first biologic drug for SLE to be approved in Europe that is not restricted to patients with a high degree of disease activity, according to AZ, which also notes it ...

Saphnelo (Anifrolumab) is instrumental in addressing autoimmune conditions by targeting and inhibiting the type I interferon receptor. Since this receptor is frequently overactive in autoimmune ...

Anifrolumab was all-but written off in 2018 ... Now given the brand name Saphnelo, the antibody is the first type I interferon receptor antagonist to be approved for marketing anywhere in the ...

T HURSDAY, Feb. 20, 2025 (HealthDay News) -- For patients with moderately to severely active systemic lupus erythematosus (SLE), anifrolumab is associated with less organ damage after 208 weeks ...

Anifrolumab (brand name Saphnelo) reduced the risk of long-term organ damage progression by about 60% in patients with moderately to severely active lupus, researchers reported in a new study ...

Anifrolumab (Saphnelo) lowered the risk of long-term organ damage progression by about 60% The drug received federal approval in 2021 Originally published on healthday.com, part of the BLOX ...